SynthesisFrontiers in oncology2026
Can risk scoring systems (R.E.N.A.L, PADUA and (MC)2 scoring systems) and related risk factors predict complications of renal ablation? a meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the predictive value of the R.E.N.A.L., PADUA, and (MC) Method: This systematic review and meta-analysis was reported in accordance with PRISMA and registered in PROSPERO. PubMed, Embase, the Cochrane Library, and Web of Science were searched from inception to May 1, 2025. The primary outcomes were overall, major, and minor complications after renal ablation in relation to the R.E.N.A.L., PADUA, or (MC) Results: A total of 25 retrospective studies involving 5,583 patients were included. Higher R.E.N.A.L., PADUA, and (MC) Conclusions: The R.E.N.A.L., PADUA, and (MC) Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024551193.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.